Table 1.
Clinical and baseline oncologic characteristics of the study cohort (n = 245).
Table 2.
Detection rate of [¹⁸F]PSMA-1007 PET/CT by PSA strata.
Fig 1.
[¹⁸F]PSMA-1007 PET/CT imaging of osseous-only recurrence of prostate cancer following radical prostatectomy.
Imaging was acquired in a 62-year-old male with biochemical recurrence (prostate-specific antigen [PSA] = 1.2 ng/mL) at 22 months post-prostatectomy; the primary tumor was graded as Gleason score 7 (ISUP Grade 3). (A) Whole-body maximum-intensity projection (MIP) of [¹⁸F]PSMA-1007 PET demonstrates multiple [¹⁸F]PSMA-1007-avid lesions distributed throughout the skeletal system. Axial PET (B, E, H), CT (C, F, I), and fused PET/CT (D, G, J) images confirm osseous metastases in the bilateral iliac bones (B–D), sacrum (E–G), and left scapula (H–J).
Fig 2.
[¹⁸F]PSMA-1007 PET/CT imaging of prostate bed recurrence with multi-site osseous metastatic castration-resistant prostate cancer.
This imaging was acquired in a 71-year-old male with castration-resistant prostate cancer at 40 months post-radical prostatectomy. The patient presented with a PSA level of 8.7 ng/mL, and the primary tumor was pathologically graded as Gleason score 8 (ISUP Grade 4). (A) Whole-body MIP of [¹⁸F]PSMA-1007 PET demonstrates diffuse [¹⁸F]PSMA-1007-avid lesions involving the pelvic region and multiple skeletal sites throughout the body. Axial PET (B, E, H), CT (C, F, I), and fused PET/CT (D, G, J) images confirm the following multi-focal lesions: Recurrence and metastatic lesions in the prostate bed, bilateral pubic bones, right ischium, and femoral neck (B–D); Osseous metastases in the sacrum and bilateral iliac bones (E–G); Osseous metastases in the thoracic vertebrae and bilateral ribs (H–J).
Table 3.
Anatomical distribution of [¹⁸F]PSMA-1007-Avid Lesions (n = 108 Therapy-Verified Cases).